List of Excipients in Branded Drug OMEPRAZOLE DELAYED RELEASE

Generic Drugs Containing OMEPRAZOLE DELAYED RELEASE

Company	Ingredient	NDC	Excipient
TIME CAP LABORATORIES INC	omeprazole 20mg	49483-731	CELLULOSE, MICROCRYSTALLINE
TIME CAP LABORATORIES INC	omeprazole 20mg	49483-731	CROSPOVIDONE
TIME CAP LABORATORIES INC	omeprazole 20mg	49483-731	DIMETHICONE
TIME CAP LABORATORIES INC	omeprazole 20mg	49483-731	FERRIC OXIDE RED
TIME CAP LABORATORIES INC	omeprazole 20mg	49483-731	GLYCERYL MONOSTEARATE
TIME CAP LABORATORIES INC	omeprazole 20mg	49483-731	HYDROXYPROPYL CELLULOSE

What are the Most Frequently-Used Excipients in OMEPRAZOLE DELAYED RELEASE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	DIMETHICONE
1	FERRIC OXIDE RED
1	GLYCERYL MONOSTEARATE
1	HYDROXYPROPYL CELLULOSE

Omeprazole Delayed-Release Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Omeprazole delayed-release products are established generic and over-the-counter medicines with limited active-ingredient patent risk but meaningful formulation, manufacturing, and regulatory barriers. The strongest commercial opportunities are in lower-cost multiparticulate systems, pediatric and geriatric dosage forms, orally disintegrating products, unit-dose suspension products, and differentiated combinations. Excipient selection must protect omeprazole from acid degradation, create reproducible intestinal release, and maintain stability throughout manufacturing and shelf life.

What is the formulation strategy for omeprazole delayed release?

Omeprazole is acid-labile. It degrades rapidly in acidic environments, including the stomach, so the dosage form must prevent contact with gastric acid before delivery to the small intestine. Delayed release is generally achieved through enteric-coated pellets, granules, tablets, or capsules.

The core formulation objectives are:

1. Create an alkaline microenvironment around omeprazole.
2. Separate the drug from acidic excipients and gastric fluid.
3. Apply a functional enteric barrier.
4. Control coating uniformity and dissolution.
5. Protect the product from moisture, heat, light, and mechanical stress.

Commercial products commonly use enteric-coated pellets filled into hard gelatin capsules or packed into unit-dose sachets. Other platforms include enteric-coated tablets, orally disintegrating tablets containing coated microgranules, and delayed-release oral suspensions.

The formulation generally has three functional layers:

Layer	Primary function	Typical excipient categories
Drug-containing core	Disperse omeprazole and stabilize it	Sugars, microcrystalline cellulose, alkaline agents, binders
Seal or subcoat	Separate the drug layer from the enteric polymer	Hypromellose, polyvinyl alcohol, polyethylene glycol
Enteric coat	Prevent gastric release and permit intestinal release	Methacrylic acid copolymers, cellulose acetate phthalate, hypromellose phthalate, plasticizers, anti-tacking agents

Product-specific compositions vary. FDA labeling for omeprazole delayed-release products identifies excipients such as sugar spheres, hypromellose, methacrylic acid copolymers, talc, polyethylene glycol, titanium dioxide, and alkaline agents in different product configurations [1, 2].

Which excipients are most important for omeprazole delayed release?

Alkalizing agents

Alkaline excipients are central to omeprazole stability. They raise the local pH and reduce acid-catalyzed degradation. Common candidates include:

• Sodium bicarbonate
• Sodium carbonate
• Disodium hydrogen phosphate
• Magnesium oxide
• Meglumine
• Sodium hydroxide, generally as a processing or pH-adjustment agent

The selected base must provide adequate stabilization without creating excessive dissolution variability. Strong alkalinity can affect coating integrity, capsule compatibility, taste, and long-term stability.

For pellet systems, the alkalizing agent may be incorporated into the drug layer or placed in a separate stabilizing layer. A separate layer can improve process control but increases coating steps and manufacturing cost.

Core substrates and fillers

Sugar spheres are widely used for drug layering because they provide a consistent surface and support fluid-bed coating. Microcrystalline cellulose can support direct compression or pellet formation. Mannitol is attractive for orally disintegrating products because it provides a cooling mouthfeel and relatively low hygroscopicity.

The core substrate influences:

• Pellet sphericity
• Coating uniformity
• Drug loading
• Friability
• Capsule fill weight
• Suspension sedimentation
• Dose uniformity

Multiparticulate cores generally offer better control than a single compressed matrix because individual pellets can be coated to achieve consistent gastric resistance.

Binders and film-forming polymers

Hypromellose is commonly used as a binder and seal-coat polymer. Polyvinylpyrrolidone can support drug layering but may increase moisture sensitivity. Hydroxypropyl cellulose and polyvinyl alcohol are alternative film-forming materials.

The binder should produce a uniform drug layer without excessive tackiness. High binder levels can slow disintegration or create dense films that complicate dissolution.

Enteric polymers

The enteric polymer determines the pH threshold and release profile. Relevant polymers include:

• Methacrylic acid-ethyl acrylate copolymers
• Methacrylic acid-methyl methacrylate copolymers
• Hypromellose phthalate
• Hypromellose acetate succinate
• Cellulose acetate phthalate

Methacrylic acid copolymers are widely used because they provide tunable dissolution thresholds and are available in aqueous and organic coating systems. Polymer selection affects gastric resistance, intestinal release, coating weight, process temperature, and regulatory comparability.

Plasticizers and anti-tacking agents

Polyethylene glycol, triethyl citrate, and acetyl tributyl citrate can improve film flexibility. Talc, glyceryl monostearate, and colloidal silicon dioxide can reduce sticking and agglomeration.

The plasticizer level requires optimization. Under-plasticized films may crack during handling. Over-plasticized films can soften, become tacky, or release drug prematurely.

What formulation architectures are commercially viable?

Enteric-coated pellets in capsules

This is the most established architecture. It supports high dose uniformity and can be adapted to multiple strengths. Capsules also allow manufacturers to use a common pellet blend across several dose presentations.

Commercial advantages include:

• Proven regulatory history
• Flexible strength scaling
• Strong control of gastric resistance
• Compatibility with sprinkle administration in some products
• Established manufacturing equipment

The main disadvantages are coating complexity, sensitivity to moisture, and the need for specialized fluid-bed processing.

Multiple-unit tablet systems

Multiple-unit pellet systems compress coated pellets into tablets. The formulation must prevent pellet rupture during compression. A cushioning excipient system, often based on microcrystalline cellulose, crospovidone, mannitol, or other deformable materials, is used to protect the enteric film.

This architecture can reduce capsule costs and improve branding, but it requires tighter control of compression force and pellet mechanical strength.

Orally disintegrating tablets

Orally disintegrating tablets can improve convenience for patients who have difficulty swallowing. The active ingredient remains protected in enteric-coated microgranules while the tablet matrix rapidly disperses in the mouth.

Typical excipient requirements include:

• Mannitol or other water-soluble diluents
• Crospovidone or croscarmellose sodium
• Low-moisture binders
• Sweeteners and flavors
• Lubricants compatible with rapid disintegration

The principal technical risk is damage to the enteric coating during tableting. Taste masking is also important because any exposed omeprazole can produce an unpleasant sensory profile.

Delayed-release oral suspension

Unit-dose packets and pharmacy-compounded suspension products provide opportunities in pediatrics, geriatrics, dysphagia, and hospital care. Sodium bicarbonate-based suspensions are commercially established because the alkaline vehicle helps stabilize omeprazole.

Suspension products require control of:

• Reconstitution time
• Sedimentation
• Redispersibility
• Dose withdrawal accuracy
• Microbial quality
• In-use stability
• Palatability

A liquid or powder-for-suspension product can compete through convenience and dosing flexibility, but it has higher packaging and stability requirements than capsules.

What excipient risks affect regulatory approval?

FDA approval of an abbreviated new drug application depends on pharmaceutical equivalence, bioequivalence, quality, and compliance with current manufacturing requirements. For delayed-release omeprazole, dissolution performance is particularly important because the product must demonstrate acid resistance followed by intestinal release.

Critical quality attributes include:

Attribute	Commercial relevance
Assay and degradation products	Measures chemical stability
Acid stage resistance	Confirms gastric protection
Buffer-stage release	Confirms intestinal release
Pellet size distribution	Affects dose uniformity and release
Enteric-coat weight gain	Controls dissolution behavior
Water activity and moisture content	Predicts degradation and coating failure
Capsule or sachet fill uniformity	Supports dose accuracy
Mechanical strength	Prevents coating rupture
Long-term stability	Determines shelf life and packaging needs

Excipient changes can affect bioequivalence even when the active ingredient and nominal strength remain unchanged. The highest-risk changes involve the alkalizing system, enteric polymer, coating weight, pellet size, and dosage-form architecture.

Manufacturers should treat the excipient system as part of the product performance platform rather than as a low-risk formulation variable. ICH quality-by-design principles support defining critical material attributes and linking them to critical process parameters [3].

What FDA regulatory status applies to omeprazole delayed release?

Omeprazole delayed-release capsules, tablets, and oral suspension products are approved prescription and over-the-counter products in the United States. The reference listed drug for many generic applications is Prilosec, originally developed by AstraZeneca. FDA-approved products include multiple strengths and dosage forms, depending on the product and applicant [1, 4].

The principal regulatory pathway for a generic delayed-release product is an ANDA. The applicant must establish:

• Pharmaceutical equivalence
• Bioequivalence
• Appropriate labeling
• Manufacturing controls
• Stability through the proposed shelf life
• Compliance with delayed-release dissolution requirements

FDA’s Orange Book identifies approved drug products and relevant patent or exclusivity information. Omeprazole products have been marketed for decades, and the original compound and core product exclusivity periods have expired [4].

When did omeprazole lose patent exclusivity?

The foundational omeprazole composition-of-matter and product patents expired many years ago. The original U.S. patent estate dates to the late 1970s and early 1980s, and generic competition has been established since the 2000s.

Current commercial protection is more likely to arise from:

• Product-specific formulation patents
• Manufacturing-process patents
• Combination-product patents
• Pediatric or other method-of-use patents
• Trademark and brand positioning
• Regulatory exclusivity for a newly approved formulation

For a specific product, the Orange Book must be reviewed by reference-listed-drug number because listed patents and expiration dates can differ between dosage forms and indications. There is no broad, active composition-of-matter barrier preventing generic development of conventional omeprazole delayed-release products.

Are Paragraph IV challenges still relevant for omeprazole?

Paragraph IV litigation was historically relevant when generic applicants challenged listed patents covering branded omeprazole products and formulations. For conventional delayed-release omeprazole, the central patent barriers have largely expired.

Current Paragraph IV exposure is more likely in a narrow situation involving:

• A newly approved delivery system
• A branded combination product
• A proprietary pediatric formulation
• A formulation with a separately listed patent
• A product-specific manufacturing process

A generic applicant targeting a conventional omeprazole delayed-release capsule typically faces greater risk from formulation development, bioequivalence failure, and manufacturing economics than from foundational compound patents.

What patent estate protects omeprazole delayed-release products?

The patent strength of a conventional omeprazole delayed-release product is generally low at the active-ingredient level and moderate at the formulation level.

Patent layer	Current competitive importance
Omeprazole composition of matter	Low; expired
Basic delayed-release capsule	Low to moderate; legacy rights largely expired
Specific pellet architecture	Moderate if a valid, unexpired patent exists
Oral suspension formulation	Moderate in a product-specific context
Pediatric administration method	Moderate, subject to claim scope
Manufacturing process	Moderate where process yields are difficult to replicate
Brand, trade dress, and packaging	Commercial rather than exclusivity protection

Formulation patents are strongest when they claim a narrow combination of excipients, coating layers, pH conditions, particle-size parameters, or manufacturing steps that produces a measurable performance advantage. Broad claims directed merely to enteric protection or alkaline stabilization are less likely to create durable exclusion in a mature generic field.

Which commercial opportunities exist in omeprazole delayed release?

Pediatric and dysphagia products

Patients who cannot swallow capsules remain an important target segment. Unit-dose suspensions, sprinkle formulations, and orally disintegrating tablets can support premium pricing compared with standard capsules.

The product must demonstrate reliable dosing after dispersion or administration with soft food. Palatability and caregiver handling are commercial differentiators.

Hospital and institutional packaging

Single-dose sachets, blister packs, and barcoded unit-dose presentations can improve medication administration and inventory control. Hospitals may value ready-to-use dosage forms even when the active ingredient is available at low cost.

Private-label OTC products

Omeprazole is established in the OTC heartburn market. Retailers can compete through:

• Lower acquisition cost
• Smaller pack sizes
• Club-store packages
• High-count bottles
• Combination products
• Alternative dosage forms

The primary commercial challenge is price compression. Differentiation must come from packaging, adherence, convenience, or combination therapy.

Combination products

Potential commercial combinations include products used with antibiotics for Helicobacter pylori eradication and products combining omeprazole with agents addressing reflux symptoms. Combination products require separate clinical, regulatory, labeling, and patent analysis.

The opportunity is greater when the combination improves adherence or simplifies a complex regimen. The risk is higher development cost and a more complicated regulatory pathway.

Contract development and manufacturing

Specialized coating capability can support licensing or contract manufacturing opportunities. Manufacturers with fluid-bed coating, pellet layering, and low-moisture packaging capabilities can serve multiple omeprazole brands without owning the active ingredient rights.

The most defensible capabilities include:

• High-throughput pellet coating
• Low-defect enteric films
• Moisture-controlled packaging
• Pediatric suspension filling
• In-process dissolution testing
• Scale-up experience for multiparticulate systems

How does omeprazole compare with other proton-pump inhibitors?

Product	Formulation challenge	Generic competition	Differentiation opportunity
Omeprazole delayed release	Acid-labile API and enteric protection	Very high	Pediatric, OTC, suspension, packaging
Esomeprazole delayed release	Similar enteric requirements, different active stereoisomer	High	Brand positioning and combinations
Lansoprazole delayed release	Multiparticulate and orally disintegrating systems	High	Pediatric and ODT products
Pantoprazole delayed release	Enteric tablets and stability control	High	Institutional and hospital supply
Rabeprazole delayed release	Acid-labile benzimidazole structure	Moderate to high	Regional and combination products

Omeprazole has one of the deepest supplier and manufacturing bases in the proton-pump-inhibitor category. That reduces development risk but also creates intense price competition.

What generic launch risks exist?

The likely launch scenarios are:

1. Standard delayed-release capsule: low patent risk, high price competition.
2. Enteric-coated tablet: moderate technical risk, possible convenience advantage.
3. Orally disintegrating tablet: moderate-to-high formulation risk, stronger differentiation.
4. Oral suspension: higher stability and packaging risk, targeted commercial opportunity.
5. Combination product: higher regulatory and clinical risk, potentially stronger market protection.

Key failure modes include acid-stage release, excessive degradation, coating damage during compression, moisture-driven instability, poor suspension redispersibility, and failure to demonstrate bioequivalence.

What is the revenue exposure for branded omeprazole?

Conventional branded omeprazole revenue is exposed to extensive generic and OTC competition. Revenue protection is more likely to come from differentiated presentations, combination products, private-label supply agreements, and channel-specific packaging than from the active ingredient itself.

A commercial assessment should separate:

• Prescription revenue
• OTC revenue
• Pediatric and specialty dosage-form revenue
• Hospital and institutional sales
• Authorized generic revenue
• Licensing and contract-manufacturing revenue

No single patent is likely to protect a standard omeprazole delayed-release capsule from generic substitution. The commercial value lies in manufacturing cost, regulatory execution, channel access, and product usability.

Key Takeaways

• Omeprazole requires an alkaline, enteric-protected formulation because the API is acid-labile.
• Multiparticulate enteric-coated pellets remain the most established platform.
• The most important excipient variables are the alkalizing agent, enteric polymer, seal coat, plasticizer, and moisture-control system.
• Foundational omeprazole patents and conventional product exclusivity have expired.
• Current patent risk is primarily formulation-, process-, combination-, or product-specific.
• Standard capsules face severe price competition.
• Pediatric suspensions, orally disintegrating tablets, sprinkle products, unit-dose packaging, and combination therapies offer stronger commercial differentiation.
• Manufacturing capability in pellet coating and moisture control can be more valuable than active-ingredient patent ownership.
• FDA approval depends heavily on acid-stage resistance, intestinal release, stability, and bioequivalence.
• Omeprazole has no biosimilar risk because it is a small-molecule drug, not a biologic.

FAQs

What is the best excipient for stabilizing omeprazole?

There is no universal best excipient. Sodium bicarbonate, sodium carbonate, phosphate buffers, magnesium oxide, and other alkaline systems can stabilize omeprazole. The preferred system depends on dosage form, target pH, moisture exposure, dissolution profile, and manufacturing process.

Can omeprazole delayed-release pellets be compressed into tablets?

Yes. Enteric-coated pellets can be compressed into multiple-unit tablets if the excipient system protects the coating from rupture. Compression force, pellet mechanical strength, cushioning excipients, and coating flexibility require optimization.

Is omeprazole delayed release the same as extended release?

No. Delayed release prevents release in the stomach and permits release in the intestine. Extended release controls the rate of release over a longer period. Omeprazole delayed-release products are designed primarily for gastric protection, not prolonged release.

Which packaging is best for omeprazole stability?

Moisture-protective packaging is generally preferred. High-barrier bottles, desiccant systems, aluminum-based blister structures, and foil sachets can reduce moisture exposure. The appropriate package depends on product water activity, shelf life, and in-use conditions.

Does omeprazole delayed release have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Omeprazole is a small-molecule drug and competes through generic drug approval, pharmaceutical equivalence, bioequivalence, and product-specific formulation development.

References

1. U.S. Food and Drug Administration. (2023). Prilosec: Omeprazole delayed-release capsules and oral suspension prescribing information. FDA.

2. DailyMed. (2024). Omeprazole delayed-release capsules: Product labeling and inactive ingredients. National Library of Medicine.

3. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. ICH.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.